Inactive Instrument

Correvio Pharma Corp Toronto S.E.

CA14159U3010

Cardiome Pharma : To Present At Canaccord Genuity Growth Conference On August 13

August 06, 2014 at 01:01 pm EDT

NASDAQ: CRME TSX: COM

VANCOUVER, Aug. 6, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that William Hunter, M.D., President & CEO of Cardiome, will present an update on the company's progress at the Canaccord Genuity Growth Conference on August 13, 2014 at 2:00 p.m. EDT in Boston. A live webcast and a replay of the company's presentation will be available on the Cardiome corporate website at www.cardiome.com.

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS(TM) (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

SOURCE Cardiome Pharma Corp.

Latest news about Correvio Pharma Corp

Mark Corrigan Departs as CEO from Correvio Pharma Corp	20-05-27	CI
Justin Renz, CFO Departs from Correvio Pharma Corp	20-05-27	CI
Correvio Pharma Corp. Announces Management Changes	20-05-27	CI
Mercury Pharma Group Limited completed the acquisition of Correvio Pharma Corp..	20-05-26	CI
Transcript : Correvio Pharma Corp. - Shareholder/Analyst Call	20-05-15
Correvio Pharma Corp. Postpones Announcement of Financial Statements for the First Quarter Ended March 31, 2020	20-05-04	CI
Correvio Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-30	CI
Correvio Pharma Corp. Auditor Raises 'Going Concern' Doubt	20-03-29	CI
Mercury Pharma Group Limited entered into an arrangement agreement to acquire Correvio Pharma Corp. for $21.3 million.	20-03-15	CI
Correvio Pharma Corp. Receives Complete Response Letter from U.S. FDA for Brinavess and Provides Update on Recent Events	19-12-24	CI
Correvio Pharma to explore sale after FDA panel setback; shares hit record low	19-12-11	RE
Correvio Pharma Corp Announces Outcome of FDA Advisory Committee Meeting Review of Brinavess for the Treatment of Recent Onset Atrial Fibrillation	19-12-10	CI
Correvio Announces Presentation of New Brinavess™ Spectrum Data	19-11-18	CI
Transcript : Correvio Pharma Corp., Q3 2019 Earnings Call, Nov 14, 2019	19-11-14
Correvio Pharma Corp. Reiterates Revenue Guidance for the Full-Year 2019	19-11-14	CI
Correvio Pharma Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-14	CI
Certain Common Shares of Correvio Pharma Corp. are subject to a Lock-Up Agreement Ending on 16-OCT-2019.	19-10-15	CI
Certain Stock Options of Correvio Pharma Corp. are subject to a Lock-Up Agreement Ending on 16-OCT-2019.	19-10-15	CI
Correvio Pharma Corp. Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application	19-09-12	CI
Correvio Pharma Corp. Announces Presentation of Brinavess Spectrum Data at the European Society of Cardiology 2019 Congress	19-09-03	CI
Transcript : Correvio Pharma Corp., Q2 2019 Earnings Call, Aug 14, 2019	19-08-14
Correvio Pharma Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-14	CI
Correvio Pharma Corp. Announces Brinavess Spectrum Data to Present At the European Society of Cardiology 2019 Congress	19-08-12	CI
U.S. Food and Drug Administration Accepts Correvio Pharma Corp.'s Resubmitted New Drug Application for Brinavess (Vernakalant)	19-07-25	CI
Correvio Pharma Corp. Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation	19-06-24	CI

Chart Correvio Pharma Corp

Duration

Period

More charts

Company Profile

Correvio Pharma Corp is a Canada-based company, which is a specialty pharmaceutical company. The Company focused on providing acute services. It's portfolio brands includes: Xydalba (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. The Company's products include Trevyent, a drug-device combination that is designed to deliver treprostinil, the treatment for pulmonary arterial hypertension.

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
KYOWA KIRIN CO. LTD.	+10.08%	9.12B
SK BIOPHARMACEUTICALS CO., LTD.	-17.63%	4.8B
YUHAN CORPORATION	+0.73%	3.8B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+16.55%	3.72B
INDIVIOR PLC	+27.76%	2.58B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.11%	2.36B
BETTA PHARMACEUTICALS CO., LTD.	-30.09%	2.11B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.15%	1.86B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals